Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Zeisel, S
Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history
By purchasing, you confirm you are a qualified researcher and agree to use this product solely for lawful research applications
Bertoluci M, Pimazoni-Netto A, Pires A, Pesaro A, Schaan BD, Caramelli B, et al
When you start with a compound that's 99%+ pure, you're removing countless variables that could shorten its reconstituted life
US$ 27.40
US$ 24.90
US$ 28.38
US$ 21.12
US$ 22.64
US$ 20.90
US$ 24.18
